Mark Rutstein, Vice President of Oncology Development of Bayer discusses the xofigo injection, a treatment method for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Xofigo (radium Ra 223) for Treatment of Patients with Castration-Resistant Prostate Cancer
